Evidence map›Paper›PMID 36145702›Full record

ArticlePharmaceutics2022

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties.

Kamelia M Amin, Ossama M El-Badry, Doaa E Abdel Rahman, Magda H Abdellattif, Mohammed A S Abourehab, Mahmoud H El-Maghrabey, Fahmy G Elsaid, Mohamed A El Hamd, Ahmed Elkamhawy, Usama M Ammar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Evaluating the Aphrodisiac Potential ofMolecules (Basel, Switzerland) · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Kamelia M AminPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Ossama M El-BadryPharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University (ACU), Giza 12566, Egypt.
Doaa E Abdel RahmanPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Magda H AbdellattifDepartment of Chemistry, College of Science, Taif University, Al-Haweiah, Taif 21944, Saudi Arabia.
Mohammed A S AbourehabDepartment of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-1348-6567
Mahmoud H El-MaghrabeyDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-4661-6612
Fahmy G ElsaidBiology Department, Science College, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0002-7754-2524
Mohamed A El HamdDepartment of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.ORCID 0000-0002-9774-0587
Ahmed ElkamhawyBK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea.ORCID 0000-0001-7398-6155
Usama M AmmarStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0NR, UK.
Mansoura University · EGCairo University · EGAhram Canadian University · EGSouth Valley University · EGTaif University · SAUmm al-Qura University · SAUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of PDE5 results in elevation of cGMP leading to vascular relaxation and reduction in the systemic blood pressure. Therefore, PDE5 inhibitors are used as antihypertensive and antianginal agents in addition to their major use as male erectile dysfunction treatments. Previously, we developed a novel series of 34 pyridopyrazinone derivatives as anticancer agents (series

Indexed as

2D-QSAR analysisin vitro enzyme assaymolecular dockingmolecular dynamic simulationPDE5 inhibitorspyridopyrazinone derivativesscaffold repurposing

Identifiers

PMID36145702
PMCPMC9501832
OpenAlexW4296283041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.